Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Blueprint Medicines Corpo...

    NASDAQ: BPMC · Real-Time Price · USD
    128.35
    0.17 (0.13%)
    At close: Jul 01, 2025, 3:59 PM
    128.39
    0.03%
    After-hours: Jul 01, 2025, 07:00 PM EDT
    0.13%
    Bid 128.3
    Market Cap 8.3B
    Revenue (ttm) 562.12M
    Net Income (ttm) -155.73M
    EPS (ttm) -2.5
    PE Ratio (ttm) -51.34
    Forward PE 139.2
    Analyst Hold
    Ask 129.59
    Volume 2,343,475
    Avg. Volume (20D) 3,364,520.6
    Open 128.20
    Previous Close 128.18
    Day's Range 128.17 - 128.52
    52-Week Range 73.04 - 128.52
    Beta 0.83

    About BPMC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol BPMC
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for BPMC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Blueprint Medicines Corporation is scheduled to release its earnings on Jul 31, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 weeks ago
    +26.09%
    Blueprint Medicines shares are trading higher afte... Unlock content with Pro Subscription
    2 months ago
    +10.89%
    Blueprint Medicines shares are trading higher after the company reported better-than-expected Q1 EPS results and raised its FY25 net product revenue guidance.
    news image

    1 week ago · businesswire.com

    BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

    NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bluep...

    4 weeks ago · youtube.com

    Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

    Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.

    news image

    1 month ago · zacks.com

    Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

    SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.

    news image

    4 weeks ago · businesswire.com

    Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders

    MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to l...

    news image

    4 weeks ago · businesswire.com

    BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders

    NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Blueprint Medicines Corporation (NASDAQ: BPMC) to Sanofi is fair to Blueprint shareholder...

    news image

    4 weeks ago · barrons.com

    Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

    The deal announced Monday is Sanofi's third of the year so far.

    news image

    1 month ago · wsj.com

    Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

    The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.

    news image

    1 month ago · businesswire.com

    VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery

    NEW YORK--(BUSINESS WIRE)-- #AI--VantAI, a leader in generative AI and proximity-based therapeutics, announced today that it has entered into a second expansion of its collaboration and license agreem...

    news image

    2 months ago · zacks.com

    Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

    BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.

    news image

    2 months ago · seekingalpha.com

    Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript

    Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communica...

    Add to Watchlist